FDA: anti-counterfeiting successes are 'drop in the bucket'; Pfizer sells PR plant to Mexico's Neolpharma;

> The FDA says its anti-counterfeiting successes are just "a drop in the bucket." Report

> Mylan ($MYL) is buying an oncology drug production plant in India for $32.5 million. Article

> Pfizer ($PFE) has sold one of the Puerto Rico plants it earmarked for closure to Mexican drugmaker Neolpharma. Article

> Biostar Pharmaceuticals has inked a $3 million deal to manufacture drugs for a Chinese hospital. Article

> The cost of many medicines in Ireland are to drop 10% after the government struck a deal with manufacturers. Article

> Tris Pharma has leased a New Jersey warehouse to accommodate a spike in manufacturing activity. Article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.